These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21695646)

  • 1. Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
    Uckert S; Stief CG
    Handb Exp Pharmacol; 2011; (204):307-22. PubMed ID: 21695646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in clinical urology.
    Ückert S; Kuczyk MA; Oelke M
    Expert Rev Clin Pharmacol; 2013 May; 6(3):323-32. PubMed ID: 23656343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.
    Uckert S; Stief CG; Mayer M; Jonas U; Hedlund P
    World J Urol; 2005 Dec; 23(6):368-73. PubMed ID: 16331503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
    Uckert S; Oelke M
    Br J Clin Pharmacol; 2011 Aug; 72(2):197-204. PubMed ID: 21745238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].
    Becker AJ; Uckert S; Stief CG
    Urologe A; 2008 Dec; 47(12):1582-7. PubMed ID: 18854969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
    Uckert S; Hedlund P; Andersson KE; Truss MC; Jonas U; Stief CG
    Eur Urol; 2006 Dec; 50(6):1194-207; discussion 1207. PubMed ID: 16815627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
    Zhang WH; Zhang XH
    Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
    Uckert S; Kuczyk MA
    Handb Exp Pharmacol; 2011; (202):527-42. PubMed ID: 21290241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
    Pimentel H; Wald M; Niederberger C
    Int J Impot Res; 2008; 20(2):145-9. PubMed ID: 18075506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile dysfunction and lower urinary tract.
    Sandner P; Neuser D; Bischoff E
    Handb Exp Pharmacol; 2009; (191):507-31. PubMed ID: 19089343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
    Sperling H; Lümmen G; Schneider T; Rübben H
    Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
    Dorsey P; Keel C; Klavens M; Hellstrom WJ
    Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common approach to managing lower urinary tract symptoms and erectile dysfunction.
    Taylor JM; Desouza R; Wang R
    Asian J Androl; 2008 Jan; 10(1):45-53. PubMed ID: 18087643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.